A Phase I trial of a mutant KRAS vaccine for pancreatic cancer prevention reached its first clinical milestone, producing KRAS-specific T-cell responses in 90% of participants in a high-risk cohort. Published in Cancer Discovery, the study reported that none of the participants developed pancreatic cancer after a median 16.5-month follow-up, and some precancerous lesions shrank or stopped progressing. The trial tests an interception strategy in individuals at elevated risk due to hereditary predisposition or concerning imaging-detected lesions. Researchers framed current standard care as surveillance followed by surgery when transformation risk rises, with high recurrence rates after resection and limited visibility for microscopic precursor disease.